XTX Topco Ltd Purchases Shares of 8,495 MoonLake Immunotherapeutics (NASDAQ:MLTX)

Key Points

• XTX Topco Ltd invested approximately $332,000 in MoonLake Immunotherapeutics, acquiring 8,495 shares during the first quarter.
• Analysts have set a consensus price target of $74.43 for MoonLake Immunotherapeutics, with several firms issuing buy ratings.
• The company reported a quarterly earnings per share of ($0.87), missing the consensus estimate of ($0.73) by $0.14.

XTX Topco Ltd acquired a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 8,495 shares of the company's stock, valued at approximately $332,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MLTX. Price T Rowe Associates Inc. MD grew its holdings in MoonLake Immunotherapeutics by 12.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company's stock valued at $181,059,000 after purchasing an additional 363,394 shares during the last quarter. Paradigm Biocapital Advisors LP raised its stake in shares of MoonLake Immunotherapeutics by 90.3% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company's stock worth $95,965,000 after buying an additional 840,731 shares during the last quarter. Marshall Wace LLP boosted its position in shares of MoonLake Immunotherapeutics by 7.9% in the 4th quarter. Marshall Wace LLP now owns 1,245,299 shares of the company's stock worth $67,433,000 after buying an additional 90,914 shares in the last quarter. Polar Capital Holdings Plc grew its stake in MoonLake Immunotherapeutics by 120.0% in the 4th quarter. Polar Capital Holdings Plc now owns 1,100,000 shares of the company's stock valued at $59,565,000 after acquiring an additional 600,000 shares during the last quarter. Finally, Fred Alger Management LLC grew its stake in MoonLake Immunotherapeutics by 1.1% in the 4th quarter. Fred Alger Management LLC now owns 673,773 shares of the company's stock valued at $36,485,000 after acquiring an additional 7,199 shares during the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Trading Down 1.3%

MLTX stock traded down $0.73 during midday trading on Thursday, hitting $54.93. The stock had a trading volume of 78,909 shares, compared to its average volume of 477,956. The company's 50-day moving average price is $49.33 and its 200 day moving average price is $43.33. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65. The firm has a market cap of $3.52 billion, a PE ratio of -19.76 and a beta of 1.27. MoonLake Immunotherapeutics has a 12-month low of $31.42 and a 12-month high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same period last year, the business posted ($0.39) earnings per share. On average, equities research analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MLTX. Wedbush restated an "outperform" rating and set a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Redburn Atlantic upgraded MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Rothschild & Co Redburn started coverage on MoonLake Immunotherapeutics in a research report on Monday, July 28th. They set a "neutral" rating and a $65.00 price target for the company. Finally, Wolfe Research raised MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target for the company in a report on Monday, May 19th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $74.43.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.